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Abstract: Cellular metabolism has recently been recognized as a hallmark of cancer. Investigating
the origin and effects of the reprogrammed metabolism of tumor cells, and identifying its genetic
mediators, will improve our understanding of how these changes contribute to disease progression
and may suggest new approaches to therapy. Drosophila melanogaster is emerging as a valuable
model to study multiple aspects of tumor formation and malignant transformation. In this review,
we discuss the use of Drosophila as model to study how changes in cellular metabolism, as well as
metabolic disease, contribute to cancer.
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1. Introduction
Cancer is a genetic disease that involves the accumulation of mutations that affect multiple
biological processes. Cancer-promoting changes include sustaining proliferative signalling, evading
growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis,
and activating invasion and metastasis, which can result in the death of the host [1]. Tumorigenesis is
also dependent on changes in cellular metabolism. Nearly a century ago, Otto Warburg observed a
metabolic shift in cancer cells toward increased use of glucose in a process called aerobic glycolysis.
However, tumor metabolism has only recently been recognized as a hallmark of cancer [1,2]. Interest
in cancer metabolism has grown rapidly in recent years, with an emphasis on understanding how
cancer metabolism is regulated, how it influences disease progression, and how these factors could be
exploited to improve cancer therapy [3].
Drosophila melanogaster is emerging as a valuable model for studying neurological disorders,
cardiovascular diseases, and cancer. Flies have many experimental advantages, including sophisticated
genetic tools, a short life cycle, and the ease with which large numbers of individuals can be examined in
well-targeted genetic screens. Genetic conservation between flies and humans is substantial, with 75%
of known human disease genes having related sequences in Drosophila [4]. Consequently, hypotheses
generated using flies often prove to be relevant to biomedicine. Drosophila has served as a platform
to develop models that recapitulate various aspects of human cancer, and its use has contributed to
revealing different aspects of human malignant tumors [5]. This review summarizes the contribution
of Drosophila to study how metabolism affects tumorigenesis and malignant transformation.
2. Metabolic Control of Tissue Growth
Nutritional status plays a pivotal role regulating metabolism and tissue growth during
development. Nutrient-sensing systems coordinate growth by connecting nutrient availability and
metabolism with the growth machinery. Insulin/insulin-like growth factor (IGF) signalling is a
universal, nutrient-sensing system. It is conserved from mammals to Drosophila and plays a central
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role regulating growth in response to nutrient availability. insulin/IGF binds receptor tyrosine kinases,
and this leads to the activation of the Ras/MAPK and PI-3K/Akt/TOR pathways. By activating those
signalling pathways, insulin/IGF coordinates multiple processes frequently deregulated in cancer,
including cellular growth, proliferation, metabolism, and cell survival. Key elements of these signalling
cascades, including PI-3K, Akt, TOR, and PTEN, are recognized oncogenes and tumor suppressors [6].
Research in Drosophila has served to determine how components of the insulin/IGF system, including
Rheb, Tsc1, and Tsc2, are organized in the insulin/Akt pathway, and has contributed to defining how
insulin/Akt controls systemic and cellular growth. Those studies (reviewed in depth elsewhere [7–9])
have expanded our knowledge of the normal physiological roles that these oncogenes and tumor
suppressors play, as well as how their dysregulation promotes disease.
3. Warburg Effect in Drosophila
Nearly a century ago Otto Warburg observed that tumor cells had altered glucose metabolism.
In the presence of oxygen, normal cells convert glucose to pyruvate through glycolysis. Pyruvate
dehydrogenase (PDH) mediates the conversion of Pyruvate to Acetyl-CoA, which feeds into the
Tricarboxylic acid (TCA) cycle and will eventually be metabolized to CO2 in the mitochondria via
oxidative phosphorylation. Under anaerobic conditions, pyruvate is converted to lactate by lactate
dehydrogenase (LDH). Warburg observed that tumor cells use glycolysis rather than the TCA cycle
and oxidative phosphorylation, even in the presence of oxygen [10,11]. This, ultimately leads to the
generation of lactate by the tumor cells and is known as aerobic glycolysis, and the ability of cancer
cells to obtain this metabolic state was termed Warburg effect. Recent studies have noted that the
Warburg effect contributes to cancer progression [2].
LDH is a key enzyme in this process. Human LDH enzymes are encoded by four separate genes,
LDHA-D, which catalyse the conversion of pyruvate to lactate. The LDHA isoform is predominantly
expressed in cancer cells and has higher affinity for pyruvate, favouring the conversion of pyruvate
to lactate [12,13]. Tumor cells frequently grow in an oxygen-poor environment and hypoxia has
been proposed as the primary signal that induces metabolic reprogramming in tumor cells [14].
In an oxygen-poor environment, the Hypoxia inducible factor-1α (Hif-1α in Drosophila) is stabilized.
At normal oxygen levels, Hif-1α is rapidly degraded. Hif-1α has been shown to regulate LDHA
expression in cancer cell lines [15]. Even though this supports the metabolic switch observed in
hypoxia, it does not explain how aerobic glycolysis is maintained in normoxic conditions. LDH is
encoded by a single gene (ImpL3) in Drosophila. Biochemical studies demonstrated that fly LDH,
like mammalian LDHA, favors the conversion of pyruvate to lactate [16]. The presence of a single LDH
gene in flies eliminates potential genetic redundancy of the LDH family members and facilitates the
analysis of its function. This, together with the sophisticated toolkit available in Drosophila, has allowed
the use of Drosophila to study the Warburg effect.
3.1. Warburg Effect in Drosophila Tumors
The Drosophila imaginal discs are epithelial structures that proliferate extensively during
larval development and, after metamorphosis, give rise to the external structures of the adult fly.
The imaginal discs have been used to model different aspects of tumorigenesis [17]. Activation of
the PDGF/VEGF-receptor (Pvr) in the imaginal discs leads to the formation of epithelial tumors that
up-regulate LDH and show aerobic glycolysis [18,19]. Pvr activation in the fly imaginal epithelium
has therefore been used as a model to dissect how aerobic glycolysis is induced and maintained in
epithelial tumor cells [19]. Pvr activation causes metabolic reprogramming by affecting glycolysis and
mitochondrial respiration. On the one hand, cells activating Pvr upregulate LDH and several glycolytic
enzymes in a Hif-1α dependent manner. On the other hand, Pvr attenuates mitochondrial respiration
by downregulating genes encoding mitochondria proteins, and by inhibiting PDH activity. One of the
primary consequences of mitochondrial dysfunction is the accumulation of reactive oxygen species
(ROS) [20,21]. ROS accumulation has two important outcomes: (1) it stabilizes Hif-1α; and (2) ROS
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activates the c-Jun amino (N)-terminal kinase pathway (JNK) pathway, which has been shown to
inhibit PDH activity [22,23]. Therefore, experiments performed in Drosophila have demonstrated
that the accumulation of ROS in tumor cells is used as a feedback mechanism to consolidate the
high-LDH/low-PDH state, and thereby to stabilize the aerobic glycolysis state.
The Notch signalling pathway regulates cell proliferation and differentiation, and has been shown
to function as both an oncogene or as a tumor suppressor [24,25]. Notch behaves as an oncogene
in the Drosophila imaginal discs, in which Notch activation leads to tissue hyperplasia and tumor
formation [26]. Notch activation also induces a switch towards increased glycolysis and reduced TCA
cycle and mitochondrial respiration in the imaginal epithelia. Interestingly, several key metabolic
regulators like the glucose transporter Glut-1, the glycolytic enzyme hexokinase A, and LDH have
been shown to be direct target genes of the Notch pathway [27].
These studies have shed light on the molecular mechanisms by which the Pvr and Notch
oncogenes promote a shift toward Warburg effect metabolism in epithelial tumors [19,27].
3.2. Warburg Effect in Normal Development
Warburg effect metabolism is thought to promote cancer cell growth by diverting glucose
metabolism toward production of amino acids at the expense of efficiency in ATP production via the
TCA cycle [28]. Although apparently inefficient, this shift favors increased biomass by the converting
nutrients into cellular building blocks to support rapid growth during normal larval development in
the fly. This depends on the activity of the Drosophila estrogen-related receptor (dERR) [29], a nuclear
receptor that regulates the expression of genes involved in glucose metabolism. dERR mutants show
lower expression of almost all glycolytic genes and die in the larval stage, presenting high levels of
circulating glucose and reduced levels of lactate and triacylglycerides. The metabolic state induced
by dERR aims to support larval growth by generating biomass from dietary carbohydrates, and it
resembles the metabolic switch observed in Warburg effect. Interestingly, multiple studies have
implicated human ERRs in cancer [30–33]. The results obtained in Drosophila raise the possibility
that ERRs might control tumor development, at least in part, by modulating cellular metabolism in a
manner that promotes a Warburg-like phenotype.
Recent work has used the Drosophila intestinal stem cell model to analyse how changes in the
glucose metabolism affect intestinal homeostasis. The Drosophila gut is a simple system in which
intestinal stem cells divide to self-renew and to give rise to a class of progenitors called enteroblasts,
which differentiate (without cell division) into two different cell lineages: absorptive intestinal epithelial
cells (enterocytes) and endocrine cells [34–36]. The mitochondrial pyruvate carrier (MPC) mediates
pyruvate uptake by the mitochondria and is crucially linked to glycolysis and mitochondrial oxidation.
In the Drosophila intestine, MPC shows high levels of expression in the more differentiated endocrine
cells, and its expression is lower in the proliferative stem cells. Interestingly, MPC mutant intestinal
cells proliferate faster than their wild type counterparts, and guts mutant for MPC develop tumorous
growths with epithelial multi-layering, characteristics of cancer. Reducing LDH levels in the pool
of intestinal stem cells has the opposite effect and leads to a reduction in the proliferation rate [37].
These results demonstrate that pyruvate oxidative metabolism plays a central role in regulating stem
cell proliferation, differentiation, and tissue homeostasis, as well as in providing additional evidence
supporting a central role of metabolism in development and tumorigenesis.
3.3. Mitochondrial Dysfunction and Tumor Progression
Pyruvate produced in glycolysis is used in the mitochondria to generate ATP and metabolites.
Mitochondrial dysfunction is common in human cancers. However, whether mitochondrial
dysfunction is a consequence of the increase in the glycolytic flux, or whether it is a driving
force in tumorigenesis, is an ongoing subject of debate [38–41]. The RasV12 oncogenic mutation
induces cell proliferation and benign tumors in Drosophila epithelial cells [42] and has been used
as a sensitized genetic background to search for cooperating factors that promote formation of
J. Dev. Biol. 2017, 5, 15 4 of 14
neoplastic tumors [43–45]. One screen identified multiple mitochondrial genes that, when mutated,
cooperate with RasV12 in the formation of malignant tumors and metastasis [44]. Interestingly,
while the genetically modified cells induce p53 and undergo cell cycle arrest and Ras-induced cellular
senescence [46], they act in a non-autonomous manner to drive the formation of tumors in the
surrounding normal cells [44]. These surprising findings may make sense in light of recent studies
showing that senescent cells secrete cytokines and growth factors known as the senescence-associated
secretory phenotype (SASP) [47]. Senescence, therefore, has concurrent and opposing roles: it has
an autonomous suppressive role aimed at eliminating tumor cells, and a non-autonomous signalling
effect mediated by the SASP phenotype that can promote overproliferation, leading to tumor formation
in nearby cells.
Drosophila genetics has been used to explore the molecular connection between mitochondrial
dysfunction and the SASP phenotype. Drosophila epithelial cells defective in mitochondrial
function and expressing RasV12 produce ROS, which activates the JNK stress-response pathway.
This represses the Hippo tumor-suppressor pathway and leads to upregulation of the secreted proteins
Unpaired/interleukin-6 and Wingless/WNT. Unpaired and Wingless induce cell proliferation and
benign hyperplasia of neighbouring tissue. Interestingly, when RasV12 is active in the surrounding cells,
activation of the Unpaired and Wingless pathways promotes malignant tumors and metastasis [44].
These observations suggest that mitochondrial defects, rather than being a consequence of the increase
in the glycolytic flux observed in cancer cells, can play an instructive role in cancer progression.
These studies may provide a context to understand the effects of mutations in respiratory-chain
complex genes that have been observed in pancreatic cancer [40], which, in most cases, also have
activating mutations in Ras [48].
4. The Link between Metabolic Diseases and Cancer
In addition to changes in cellular metabolism, metabolic dysfunctions can influence cancer.
Obesity is a complex metabolic disorder that results in excessive accumulation of dietary lipids.
Changes in lifestyle, linked to increased consumption of energy rich foods and more sedentary
behaviour, increase the incidence of obesity-associated metabolic disease, including type 2 diabetes.
There is a strong clinical association between these metabolic disorders and the risk of specific types of
cancer, and patients with metabolic dysfunction have higher cancer-related mortality [49–53]. However,
the mechanisms that link metabolic morbidities and cancer are not well understood. We discuss here
how Drosophila has been used to investigate the obesity-cancer interaction.
4.1. Factors Controlling Obesity
In addition to the impact of changes in life style, human obesity has a strong genetic
component [54]. Genome-wide screens using Drosophila have been used to identify novel genetic
factors that can contribute to obesity [55]. An RNAi-based in vivo screen identified ~500 genes that
led to changes in fat levels in adult flies. 60% of these genes have human orthologues. Depletion of
those candidates, specifically in the fly adipose tissue, created a role for the conserved hedgehog (hh)
signalling pathway. Downregulation of the hedgehog pathway in the fat body, via the depletion of
hh, iHog, and smoothened, or the transcription pathway cubitus interruptus, led to a marked increase
in triglyceride levels. In a mouse model, fat-specific hedgehog-activation led to lean mice with a
strong reduction in fat tissue, revealing conservation between flies and mammals in adipocyte tissue
physiology [55].
Genome-wide transcriptome profiling comparing starved versus fed flies implicated the lipase
gene brummer (bmm) in obesity [56]. The expression of bmm is controlled by the nutritional status of
the animal. bmm downregulation is sufficient to cause obesity and, reciprocally, flies overexpressing
bmm showed a depletion in organismal fat stores, resembling nutrient-deprived animals. bmm encodes
the lipid-storage, droplet-associated triacylglycerol lipase, which is a homolog of the human adipocyte
triglyceride lipase. The obesity-related phenotype observed in flies depleted of bmm, together with
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this evolutionary conservation, suggest that regulation of this family of genes could be involved in
human obesity [56].
In addition to genetics and the environment, studies in human populations have demonstrated
that the parental nutritional state can influence the metabolism of the offspring for multiple
generations [57–60]. Even though different molecular mechanisms for imprinting, including DNA
methylation, histone modifications, and non-coding RNA have been implicated in this process [61],
how intergenerational phenotypes are initiated, stabilized, and transmitted remains largely unknown.
As in humans, the nutritional state of the parents affects the metabolism of the offspring in flies: an
increase in paternal dietary sugar affects metabolism in the offspring. The analysis of flies grown in
higher sugar diet (HSD) detected changes in the chromatin state of mature sperm and in the embryos
they produce that led to obesity in the offspring. Interestingly, many genes involved in cytosolic
and mitochondrial metabolism are found in those chromatin regions, which might account for the
metabolic changes observed in the offspring. The use of a Drosophila has allowed the identification of
gene networks involved in parental-induced intergenerational metabolic reprogramming. This gene
signature is conserved from flies to mice and humans [62], suggesting that similar gene networks may
regulate obesity susceptibility in humans and Drosophila.
4.2. Connecting Obesity and Cancer
There is a clinical association between obesity and several types of cancer. A primary consequence
of obesity is the development of insulin-resistant type 2 diabetes. When the body becomes resistant to
insulin, it compensates by producing more insulin [63]. In addition to its glucose regulatory function,
insulin is a mitogen that promotes tissue growth [64], and, thus, chronic elevation of systemic insulin
levels is a candidate for promoting tumorigenesis in obese and diabetic patients.
The insulin pathway is conserved from flies to humans, and feeding flies with HSD induces
hyperinsulinemia and insulin resistance [65], which resembles the metabolic defects observed in obese
humans. Activation of the oncogenes Ras and Src is common in multiple human cancers [66], and this
genetic background has been used in Drosophila to study epithelial tumor formation [67]. Clones of cells
activating Ras and Src in the imaginal discs of Drosophila do not develop into tumors when raised on a
control-normal diet; however, they form malignant tumors with aggressive metastatic-like behaviour
when the flies are fed on a HSD [68]. While most tissues in flies fed in HSD are insulin-resistant,
cells activating the oncogenes Ras-Src express high levels of the insulin receptor. This makes these
tumors sensitive to the elevated levels of systemic insulin produced by these nutritional conditions.
High insulin signalling in the Ras-Src-expressing cells upregulates the signalling molecule Wingless
(WNT), which, in turn, causes a further increase in Insulin receptor levels, creating a positive feedback
loop that reinforces this program. The increase of insulin receptor levels in Ras-Src tumors makes them
sensitive to insulin, allowing them to use circulating sugar to fuel their growth [68].
How do tumors in animals fed on high sugar trigger the initial upregulation of the insulin
receptors to benefit from high systemic insulin? Further studies by the Cagan group identified
the salt-inducible kinases (SIKs) as proteins induced by activation of Ras and Src in flies fed in
HSD [69]. SIKs are serine/threonine kinases of the AMP kinase family of proteins that control
metabolic homeostasis in mammals and flies [70–75]. SIKs can induce tissue growth by repressing the
Hippo tumor suppressor pathway [76]. HSD induces SIKs in cells activating the oncogenes Ras and
Src. This inhibits the Hippo kinase cascade that results in the activation of the Hippo transcriptional
activator, the oncogene Yorkie, which induces the expression of its target gene Wingless [69]. SIKs act
as sugar sensors that link the nutritional status to Hippo activity. By using this mechanism, the Ras-Src
cells respond to changes in the diet to promote tumor growth in conditions of HSD. The finding that
diet influences tumor development in Drosophila opens the possibility to use genetic tools to further
analyse the molecular links between obesity and the risk of cancer.
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4.3. Drosophila Fat Body to Identify Drugs that Modulate Lipid Metabolism
Drosophila has also been used as a platform to search for chemical compounds regulating signalling
pathways involved in cancer and metabolism [77]. WNT signalling, in addition to its implications
in specific types of cancer, has been shown to control adipocyte development [78,79]. Adipocytes
play central roles in controlling fat metabolism and storage in mammals. The adipocytes in the
Drosophila fat body contain numerous lipid droplets and store most of the triglycerides of the fly,
having a similar metabolic role to mammalian adipose tissues. Axin is a negative regulator of the
Wingless cascade in Drosophila, and Axin depletion results in an increase in Wingless pathway activity.
Interestingly, Axin mutants show reduced triglycerides and a smaller amount of fat body tissue,
and the adipocytes in Axin mutants are reduced in size and contain fewer oil droplets. The Axin
mutant background was used to screen for compounds that regulate the Wingless pathway and
lipid metabolism. That screening resulted in the identification of peptide boronic acids (a family of
proteasome inhibitors) as chemical compounds that reduce Wingless signalling and rescue the fat body
defects observed in Axin mutants [77]. This work exemplifies how fly models can be used to identify
candidate drugs.
4.4. TGF-βs as Regulators of Obesity and Insulin Resistance
A high-fat diet can also induce type 2 diabetes in humans. Adipose tissue, in addition to
functioning as the site of fat storage, behaves as an endocrine organ that secretes signalling molecules
that control metabolic homeostasis [80,81]. The signalling molecule TGF-β is secreted by the adipose
tissue and has been identified as a critical mediator of diet-induced insulin resistance in mice, although
the mechanism by which TGF-β controlled insulin resistance was not elucidated [82]. In Drosophila,
a high fat diet (HFD) leads to elevated circulating triglyceride and glucose levels, and insulin resistance,
akin to obese mammals. This has allowed the use of Drosophila genetics to explore diet-induced insulin
resistance [83]. The Drosophila gene glass bottom boat (gbb) is a TGF-β family member with functions
in growth, morphogenesis, and energy homeostasis [84–87]. Consistent with the result obtained in
mice, the protein levels of the TGF-β Gbb are increased in HFD conditions, and overexpression of
gbb in the Drosophila fat body is sufficient to trigger obesity and insulin resistance, recapitulating the
HFD phenotypes. Conversely, depletion of gbb results in a rescue of the HFD-induced metabolic
phenotypes. Gbb signalling promotes insulin resistance by increasing the expression of the gene
tribbles [88]. TRB3, a mammalian homolog of Drosophila tribbles, functions as a negative modulator of
Insulin pathway in mice by regulating the serine-threonine kinase Akt, which is a central mediator of
insulin signalling. TRB3 physically interacts with Akt and represses its kinase activity, causing insulin
resistance [89]. In agreement with those observations, Drosophila Tribbles represses Akt in the fat body.
HFD-fed mice upregulate TGF-β and the orthologous protein TRB3, which inhibited insulin signalling.
The combination of studies in mice and flies shed light on the mechanisms by which TGF-β controls
obesity and diabetic phenotypes [88,89].
Defects in mitochondrial activity have been associated with obesity, and both mitochondrial
perturbations and obesity influence cancer progression. Accumulating evidence shows that
mitochondrial alterations in one organ can have systemic effects through hormonal signalling [90,91].
Drosophila has been used to explore how mitochondrial defects can modulate fat accumulation in
distant organs. This analysis found that mitochondrial perturbations in the muscle can influence
mitochondrial function and metabolism in the fat body, leading to triglyceride accumulation,
characteristic of obesity [83]. This work identified the TGF-β ligand, Activin, as the key element
mediating mitochondrial synchrony between the muscle and the fat body. Activin is expressed at low
levels in wild-type muscles, but its expression is increased in muscles with defects in mitochondrial
activity. Activin secreted by the muscles acts systemically to impair mitochondrial activity and increase
lipid accumulation in the fat body. This work identified a molecular mechanism whereby Activin
behaved as a hormone to regulate “mitochondrial synchrony” between organs. The results obtained
in Drosophila are in good agreement with previous observations showing that Activin represses
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mitochondrial function and lipid accumulation in mammals [92], and they suggest that this mechanism
is conserved.
5. Drosophila as a Model to Study Cachexia
More than 80% of advanced human cancer patients show signs of loss of body mass caused by
degeneration of skeletal muscle and fat storage wasting, a disorder known as cachexia [93]. Cachexia
remains as a major hurdle in cancer treatment, in part because the molecular mechanisms that drive
wasting remain elusive. As in humans, the presence of malignant tumors in Drosophila impairs muscle
function and causes systemic wasting [94,95]. The induction of neoplastic tumors in flies leads to
metabolic reprograming in the muscle that results in a strong downregulation of genes involved in
energy metabolism, including glycolysis, TCA cycle, and Oxidative phosphorylation. This leads to
mitochondrial degeneration and a reduction in ATP levels in muscle cells. Drosophila tumors produce
ImpL2, a homolog of the secreted insulin growth factor-binding protein. Elevated ImpL2 release
can reduce systemic insulin signalling in flies with malignant tumors. Depletion of insulin activity
is sufficient to induce cachexia-like phenotype. Notably, suppression of ImpL2 increases insulin
signalling and alleviates some wasting phenotypes associated with these tumors [94,95], suggesting a
potential therapeutic approach to cachexia.
6. Metabolism and Angiogenesis
Angiogenesis is the physiological process through which new blood vasculature is formed.
Tumors often grow in nutrient- and oxygen-poor environments, and angiogenesis is one of the
strategies used to obtain nutrients and oxygen. Consequently, angiogenesis is a key target in cancer
treatment [1]. In Drosophila, the tracheal system has an analogous role to the mammalian circulatory
system, providing internal organs with oxygen [96,97]. Similar to vertebrate capillaries, the tracheal
system responds to low oxygen levels by generating new branches via Hif-1α and Fibroblast
Growth Factor signalling [98,99]. Angiogenesis also operates in neoplastic Drosophila tumors [100].
Angiogenesis is thought to be driven by signals secreted by oxygen-deprived target cells. However,
a recent study in Drosophila has identified a new mechanism by which nutritional status regulates
angiogenesis in the Drosophila larval gut [101]. Tracheal tubes in the gut are in close proximity to axons
that emanate from insulin-producing neurons in the Drosophila brain. Those neurons guide changes in
tracheal architecture through expression of Insulin-like peptide 7 (Ilp7), as well as pigment dispersing
factor (Pdf), a neuropeptide that shares similarities to the vertebrate Vasoactive Intestinal Polypeptide.
Ilp7 and Pdf control the growth of the tracheal cell terminal branches in response to nutritional cues
received by those neurons. This work illustrates a new mechanism that couples the metabolic state
with the process of angiogenesis. It will be of interest to see whether future studies show similar links
between systemic metabolism and angiogenesis in human cancer progression.
7. Metabolism and Cell Competition
Tumors have several strategies, beyond angiogenesis, for obtaining nutrients. Cancer cells
can use amino acids produced from the degradation of extracellular proteins internalized via
macropicnocytosis, from entosis of living cells, from phagocytosis of apoptotic bodies, and from
lipids from the extracellular phospholipids [2]. For example, cells activating the oncogene K-Ras kill
and engulf surrounding cells by a process known as cell competition [102], and accumulating evidence
suggests that cell competition contributes to cancer [103–106]. Cell competition was first described
in Drosophila in the 1970s [107] and serves as a fitness selection mechanism by which “more fit” cells
(winners) recognize and eliminate their “less fit” neighbours (losers) [105].
Metabolic pathways active in tumor cells are controlled by oncogenes [108,109], and oncogene
activation can trigger cell competition [110]. Oncogenic Ras promotes cell growth and proliferation
in Drosophila by activating the PI-3K pathway and by increasing Myc protein levels [111]. Drosophila
cells expressing high levels of the Myc oncogene acquire a “supercompetitor” status and induce
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apoptosis in normal surrounding cells that, when surrounded by those supercompetitor cells,
become losers [112,113]. Myc controls cellular metabolism in different ways. In the Drosophila
fat tissue, Myc regulates glucose and lipid metabolism to favor the storage of nutrients lipids and
sugars [114]. In a context of cell competition, Myc-expressing cells reprogram their metabolism
towards enhancing glycolysis in a p53-dependent manner. In absence of p53, cells upregulating Myc
lose their supercompetitor status and cannot induce apoptosis in surrounding normal cells, so that
the population of Myc-expressing cells cannot increase in size [115]. This suggests that metabolic
reprogramming might play a crucial role in early phases of disease, whereby emerging cancer cells
might expand by boosting glycolysis.
Cell competition involves the induction of apoptosis in the loser cells and, in some cases, this is
accompanied by the engulfment of the losers by the winners [102,104,116,117]. A recent study identified
the conserved miRNA, miR-8, as a cooperative partner of the Epidermal Growth Factor Receptor (EGFR)
oncogene [104]. Coexpression of EGFR and miR-8 in the imaginal wing epithelium results in the
formation of metastatic tumors. An interesting characteristic of those tumors is that they contain giant
polyploid cells, which induce apoptosis and engulf their neighbouring cells. Interestingly, inhibition of
apoptosis or engulfment completely suppress the formation of the polyploid cells and, consequently,
tumors and metastasis are not formed. These observations suggest that cancer polyploid cells may
need to engulf surrounding cells in order to obtain nutrients that allow them to grow and become
malignant [104].
Downregulation of the gene calderón (cald) also induces cell competition in Drosophila epithelia. cald
encodes a protein with homology on the major facilitator super-family of organic cation transporters,
and these transporters are believed to function mainly in the uptake of sugars and other organic
metabolites. The cald gene is regulated by the insulin pathway and is required for insulin-regulated cell
growth and proliferation. Interestingly, cells mutant for cald are viable when surrounded by other cald
mutant cells, but they are eliminated by cell competition when their neighbours are normal cells [118].
This report suggests that the metabolic state of the cell can impact in the “winner” vs. “loser” status
and hence induce cell competition and tumor progression.
8. Perspectives
In this review, we have discussed how the use of Drosophila melanogaster has contributed to
the study of mechanistic links between metabolism and cancer. Metabolic changes are emerging as
important drivers of malignancy, and cancer-specific metabolic alterations are becoming an important
research theme. Drosophila has been broadly used to study how metabolism is orchestrated to support
biological processes, including growth, proliferation, and apoptosis in normal development. The fact
that Drosophila shares a great degree of gene conservation with humans has made of this model
organism a valuable tool for the identification and analysis of genes involved in cancer metabolism.
To date, most studies have been focused on alterations in glucose metabolism. However, cancer
cells also use nutrients like glutamine, amino acids, essential fatty acids, etc. Given the underlying
similarity in metabolism, future studies using fly models should be used to explore links between
nutrient utilization and disease progression. A variety of obesity-related models have been developed
in Drosophila. The combination of these with available fly tumor models should be a fruitful path to
investigate the molecular connections between diet, obesity, diabetes, and cancer. Finally, the impact
of metabolites produced by gut microbiota on tumor progression is only starting to be appreciated.
Drosophila has been extensively used to investigate the contribution of microbiota on insect behaviour,
immunity, and metabolism. This will allow the fly to be used to study the influence that metabolic
changes mediated by the activity of the microbiota have on disease progression.
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